Share:

Dr. Candice McCoy is Executive Director, Cellular Therapy, Global Drug Development, at Bristol Myers Squibb where she oversees global clinical development of BREYANZI®, an autologous CD19-directed CAR T cell therapy. Previously, Candice was Vice President, Clinical Affairs and Global Drug Safety at Dendreon, held clinical development positions at Berlex/Schering AG and Immunex, and founded Phase Plus Consulting, LLC. She has made significant contributions to global regulatory submissions for novel therapies in cancer indications, including PROVENGE®, an autologous immunotherapy for certain prostate cancers, and BREYANZI.

Share: